Build my stack
Home · Guides · MOTS-c Dosage

MOTS-c Dosage: No Established Human Dose, and How the Units Work

Ready to buy? the vendor scorecard ranks every seller we review on lab tests, shipping and price, with reader codes.
Disclosure: affiliate links below may earn the Bureau a commission at no cost to you.

The short answer

No human dose of MOTS-c has been established. FDA's briefing for its July 2026 advisory committee found no published clinical studies of MOTS-c in people, and the only registered trial of MOTS-c itself that a ClinicalTrials.gov search found (NCT07505745, a fixed daily dose for 12 weeks) is still recruiting and lists no dose in mg. The doses in the literature are from rodents, 0.5 to 15 mg per kg, mostly by injection into the abdominal cavity, and the community protocols that Peptulator summarises, 5 to 10 mg per injection two or three times a week, have no trial behind them. On 23 July 2026 the advisory committee voted 7 to 5 to recommend MOTS-c for the FDA's 503A compounding list, against FDA staff advice. It is not on that list, but on 30 October 2026 HHS published an interim, non-binding policy saying it does not intend to take enforcement action over MOTS-c that licensed pharmacies or physicians compound for injection under the skin or into muscle, under ten conditions that include a prescription for an individual patient.

Best vendor for MOTS-c right now: Amino Club, Code 100: 20% off.

Bureau Score 4.7, 0 of 1 independent tests passed (Finnrick). Compare every store. Reader codes were checked on the vendor's cart; offer terms are the vendor's and can change. Affiliate link: we earn a commission if you order. Laboratory research use only, not for human use.

This page is a research-use reference. It reports what regulators, trial registries and published studies say, and what is reported in the community, and it does not recommend any dose. Every figure below carries its source and the date it was checked, 31 October 2026. Animal data is labelled as animal data.

What People Report Running (Not a Recommendation)

Reported MOTS-c protocols are unusual for a peptide: whole-milligram doses, with the commonly reported range given as 2.5 mg to 10 mg per injection, most often 5 to 10 mg two or three times a week and sometimes a short daily course. That is how Peptulator, the Bureau's calculator site, summarises it on its MOTS-c page, reviewed 3 September 2026. None of these schedules comes from a human trial, and the same page describes MOTS-c as not well characterised in humans. When you compare sources, check whether a figure is per injection, per day or per week, because the same number gives very different totals.

FDA's briefing adds the market context. Injectable MOTS-c is sold online for uses such as regulating mitochondrial energy, improving glucose regulation and promoting weight loss, it has no USP or NF drug substance monograph, and it is not a component of an FDA-approved drug.

Take a 10 mg vial as the example. At 5 to 10 mg per injection it holds one or two doses, which is why the amount of water added decides whether a single draw fits a 1 mL syringe. The arithmetic is worked through below.

Where the Numbers Come From

In people: one analogue trial and one trial now recruiting

No MOTS-c dose-finding study has been published. FDA's briefing document for the 23 July 2026 Pharmacy Compounding Advisory Committee says its own search of the published literature found no clinical studies of MOTS-c given to humans, and that it identified no pharmacokinetic data. Two registered trials are relevant. Neither gives a MOTS-c dose: one tests an analogue, and the other does not state its dose.

TrialDesignWhat the record and sponsor show
CB4211, CohBar
NCT03998514
Phase 1a/1b, randomized, double-blind, placebo-controlled, subcutaneous injection. Completed 19 April 2021, 88 enrolled per the registry. CB4211 is a different molecule: the company calls it an analog of MOTS-c. The registry lists dose levels without numbers. In its August 2021 topline release the company said the Phase 1b gave 25 mg once daily for four weeks to 20 obese adults with fatty liver disease, was well tolerated with no serious adverse events, and lowered ALT, AST and glucose more than placebo. Liver fat fell in both groups. Company report, not peer reviewed.
MOTS-MET, Hudson Biotech
NCT07505745
Phase 2a, randomized, double-blind, placebo-controlled, MOTS-c itself by subcutaneous injection. 120 planned, adults 18 to 65 with prediabetes and a BMI of 27 to 40. Started 2 February 2026, primary completion estimated 14 February 2027. Regimen listed as "fixed dose once daily for 12 weeks" with a 4-week safety follow-up. The record states no dose in mg. Status Recruiting, no results posted.

Because CB4211 is an analogue, its 25 mg figure is not a MOTS-c dose. The MOTS-c trial is the one to watch, and until it reports, any dose you see quoted for people is a convention rather than a finding.

In animals: rodent doses

The first MOTS-c paper (Lee et al., Cell Metabolism, 2015) described a 16-amino-acid peptide encoded in mitochondrial DNA and reported that, in mice, it prevented diet-induced obesity and age-related and diet-induced insulin resistance. The doses below are animal data, per kilogram of body weight.

StudyAnimalsDose and routeDuration
Lee et al. 2015Male CD-1 mice, 8 weeks old, high-fat diet0.5 mg/kg/day, intraperitoneal, daily8 weeks (a 3-week arm also reported)
Lee et al. 2015C57BL/6 mice, including 3-month and 12-month-old males5 mg/kg/day, intraperitoneal7 days
Kim et al. 2019, as summarised by FDA17-week-old male mice made obese by high-fat diet2.5 mg/kg, intraperitoneal, twice a day3 days
Lu et al. 2019, as summarised by FDAOvariectomised female mice5 mg/kg/day, intraperitoneal12 weeks
Reynolds et al. 2021, as summarised by FDAYoung, middle-aged and old mice5 mg/kg intraperitoneal (treadmill test); 15 mg/kg/day; 15 mg/kg three times a weekAcute; 2 weeks; from 23.5 months of age

Sources: Lee et al. 2015 (PMC full text, Methods and figure legends) and FDA's briefing document, which summarises the later papers. The Bureau did not open Kim, Lu or Reynolds directly.

In the 2015 paper's 8-week high-fat-diet experiment, treated mice weighed about 20% less than vehicle-treated mice at the end of treatment, according to FDA's summary. A per-kilogram rodent dose does not carry over to people. FDA's briefing makes the same point in its own words: the studies were limited to in-vitro and rodent models, assessments of dose-response relationships for MOTS-c are missing, and the clinical relevance of the findings is currently unknown.

The mechanism background is in the MOTS-c peptide guide, and the claimed effects are weighed against the evidence in MOTS-c benefits.

MOTS-c at AminoClub

Stocked as a standing catalogue item with batch testing published, which matters more than usual for a compound where dose precision is already uncertain. A 10mg vial is the standard unit and covers one to two weeks at the common range. Research use only.

Check MOTS-c at AminoClub Compare all vendors

Reconstitution: A Worked Example With the Arithmetic

Syringe units measure volume, not peptide. A U-100 insulin syringe holds 100 units per mL, so the same number of units delivers a different dose depending on how much water went into the vial. The calculation has two steps, shown here for a 10 mg vial with 2 mL of bacteriostatic water.

  1. Concentration = milligrams in the vial ÷ millilitres of water. 10 mg ÷ 2 mL = 5 mg/mL.
  2. Volume to draw = dose ÷ concentration. For 1 mg: 1 mg ÷ 5 mg/mL = 0.2 mL. On a U-100 syringe, 0.2 mL × 100 units per mL = 20 units.

So with 2 mL in a 10 mg vial, 1 mg is 20 units, 2.5 mg is 50 units and 5 mg is 100 units, which is a full 1 mL syringe. The same method gives every row of this table.

Water added to 10 mgConcentration1 mg2.5 mg5 mg
1 mL10 mg/mL10 units (0.1 mL)25 units (0.25 mL)50 units (0.5 mL)
2 mL5 mg/mL20 units (0.2 mL)50 units (0.5 mL)100 units (1 mL)
3 mL3.33 mg/mL30 units (0.3 mL)75 units (0.75 mL)150 units (1.5 mL)

At the 5 to 10 mg per injection that is reported, a 10 mg vial in 2 mL needs 100 to 200 units, so at the top of that range a single draw does not fit a 1 mL syringe. Check any other vial size, water volume or dose with the Peptulator MOTS-c dosage calculator. The handling steps are in the reconstitution guide, and the diluent is covered in the bacteriostatic water guide.

Correction, 31 October 2026. Earlier versions of this page printed the unit figures at half the correct values (for example 25 units for 2.5 mg with 2 mL of water, where the correct figure is 50). The table above is correct and matches the Peptulator calculator.

Bacteriostatic water at AminoClub. The benzyl alcohol preserved diluent that makes a multi week vial workable. Ordering it alongside the peptide avoids the classic problem of a vial arriving with nothing to mix it with. Research use only.

Check bacteriostatic water at AminoClub

Frequency, Cycle Length and Timing: None of It Is Tested

No trial has compared MOTS-c schedules, cycle lengths or injection timing. The only registered MOTS-c trial found uses a fixed dose once daily for 12 weeks with a 4-week safety follow-up (NCT07505745), and the CB4211 analogue was given once daily for four weeks in its Phase 1b (company report). Two or three injections a week is how Peptulator summarises the reported protocols, and that is a convention. Cycle lengths, breaks and timing around training have no published human data behind them.

A higher dose is not simply a stronger one. FDA's briefing says the potential safety risks of MOTS-c in humans are unknown and that dose-response relationships are missing, and it says it cannot rule out immunogenicity, an immune response to the peptide, from impurities or aggregates in the acetate form, especially when injected. What has been reported on tolerability is collected in the MOTS-c side effects page, and the timeline people describe is assessed in the before and after page.

MOTS-c at Pantheon. The second stocked source the Bureau scores for this compound, listed with a batch certificate of analysis. Worth comparing on price per milligram before committing to a multi vial block. Research use only.

Check MOTS-c at Pantheon

Where MOTS-c Stands With FDA

MOTS-c is not a component of an FDA-approved drug and has no USP or NF monograph, according to FDA's July 2026 briefing document. It was nominated for the 503A bulk drug substances list, one of the routes by which licensed pharmacies may compound from a bulk ingredient, and FDA evaluated it for obesity and osteoporosis.

FDA staff's briefing proposed not adding MOTS-c to the list, citing the lack of human safety and effectiveness data. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 7 to 5 to recommend adding it anyway (STAT, 24 July 2026). The vote is advisory, FDA does not have to follow it, and any change would come through a proposed rule with public comment. The Bureau's legal status guide, updated in October 2026, records that MOTS-c is not on the list and that no proposed rule has been published.

On 30 October 2026 HHS published an interim enforcement discretion policy for 503A compounding of six peptides, MOTS-c among them (Federal Register, 91 FR 68526). HHS says it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician that compounds a product from one of them when ten conditions are met, among them a certificate of analysis for the ingredient, a single active ingredient, MedWatch reporting of serious adverse events and a prescription for an individual patient. For MOTS-c it covers subcutaneous or intramuscular injections. Among its reasons, HHS cites a randomized placebo-controlled trial of a MOTS-c analogue that "reported no serious adverse events at an exposure well above the compounded regimen": a trial of an analogue, not of MOTS-c itself. The policy calls itself interim, says it is not binding, and does not make MOTS-c an approved drug or extend to research-use-only vials, which it says HHS wants to discourage. Our explainer of the published policy lists all ten conditions.

Storage and Sourcing

MOTS-c has no approved label, so there is no official in-use shelf life to quote, and any storage claim for a mixed vial should be treated as unverified. The storage guide covers general peptide handling, and the longevity context is in the longevity category page.

Vendor comparisons for the two sources linked on this page are in the AminoClub review and the Pantheon review. Research use only.

Key Takeaways

  • No human dose of MOTS-c is established, and FDA's briefing found no clinical studies of MOTS-c in people
  • A Phase 2a trial of MOTS-c (NCT07505745) is recruiting: fixed dose once daily for 12 weeks, no dose in mg in the record, no results posted
  • The CB4211 analogue was given at 25 mg once daily for four weeks in a Phase 1b, which is a different molecule
  • Rodent studies used 0.5 to 15 mg per kg by injection, which is animal data and not a human dose
  • Reported community protocols (Peptulator's summary: 5 to 10 mg per injection, two or three times a week) have no trial behind them
  • With 2 mL of water in a 10 mg vial the concentration is 5 mg/mL: 1 mg is 20 units, 2.5 mg is 50 units and 5 mg is 100 units on a U-100 syringe
  • The FDA advisory committee voted 7 to 5 on 23 July 2026 to recommend MOTS-c for the 503A list; it is not listed, but since 30 October 2026 an interim HHS policy covers pharmacy-compounded MOTS-c injections under ten conditions

See also: SS-31 (elamipretide) dosage on the FDA label and in the trials.

Frequently Asked Questions

What is the MOTS-c dosage?

No human dose of MOTS-c has been established. FDA's briefing for its July 2026 advisory committee found no published clinical studies of MOTS-c in people, and the registered Phase 2a trial NCT07505745 lists a fixed dose once daily for 12 weeks without a figure in milligrams. Rodent studies used 0.5 to 15 mg per kg, and the community protocols that Peptulator summarises, 5 to 10 mg per injection two or three times a week, have no trial behind them. This is research information, not a recommendation.

Has MOTS-c been tested in humans?

Not in a published study that FDA's briefing identified. The registry lists NCT07505745, a Phase 2a placebo-controlled trial of MOTS-c by subcutaneous injection in adults with prediabetes and overweight or obesity, which was recruiting with no results posted on 31 October 2026. A different molecule, the MOTS-c analogue CB4211, completed a Phase 1a/1b trial (NCT03998514), and its sponsor reported it was well tolerated with no serious adverse events.

How much bacteriostatic water do you add to a 10 mg vial of MOTS-c?

The volume is a choice, and it sets the concentration. Adding 2 mL to a 10 mg vial gives 5 mg/mL, so 1 mg is 0.2 mL, which is 20 units on a U-100 syringe, and 5 mg is 100 units. Adding 1 mL gives 10 mg/mL, where 1 mg is 10 units, and adding 3 mL gives 3.33 mg/mL, where 1 mg is 30 units.

What doses were used in the MOTS-c animal studies?

In mice, the 2015 Cell Metabolism paper by Lee and colleagues gave 0.5 mg/kg/day by intraperitoneal injection for 8 weeks in a high-fat-diet experiment and 5 mg/kg/day for 7 days in insulin-sensitivity experiments. Later mouse studies summarised in FDA's briefing used 2.5 mg/kg twice a day for 3 days, 5 mg/kg/day for 12 weeks and 15 mg/kg/day for 2 weeks. These are animal data and are not human doses.

What are the benefits of MOTS-c?

In mice, MOTS-c reduced weight gain on a high-fat diet and improved insulin sensitivity, and treated mice weighed about 20% less than vehicle-treated mice after 8 weeks in the original experiment. No human benefit has been shown. FDA's briefing says there is a lack of evidence to evaluate effectiveness, and the Phase 2a trial NCT07505745 measures insulin sensitivity at 12 weeks and has no results yet.

What are the side effects of MOTS-c?

Human safety is unknown. FDA's briefing says it found no human exposure data for MOTS-c by any route, and its adverse event database searches through 9 March 2025 returned no reports, which is not evidence of safety. In the CB4211 analogue trial, the sponsor reported no serious adverse events and mild to moderate injection site reactions as the only adverse events in more than 10% of subjects.

Is MOTS-c FDA approved, and is it on the compounding list?

MOTS-c is not a component of any FDA-approved drug and is not on the 503A bulk drug substances list. On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 7 to 5 to recommend adding it for obesity and osteoporosis, against the advice of FDA staff; the vote is advisory, and a listing would come through a proposed rule with public comment. Separately, on 30 October 2026 HHS published an interim policy naming MOTS-c among six peptides it does not intend to take enforcement action over when a State-licensed pharmacy, Federal facility or licensed physician compounds them under ten conditions, for MOTS-c as an injection under the skin or into muscle. The policy says it is not binding, and it is not an FDA approval.

How long should a MOTS-c cycle run?

No trial has tested cycle length, breaks or timing around training, so any figure is a convention. For reference, the registered Phase 2a trial NCT07505745 runs once daily for 12 weeks with a 4-week safety follow-up, and the CB4211 analogue Phase 1b ran once daily for four weeks. Neither is a recommendation for use outside a trial.

Sources

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443-454, PMID 25738459 (mouse data; full text on PMC4350682). Checked 31 October 2026.
  2. FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c free base and MOTS-c acetate), Pharmacy Compounding Advisory Committee, 23 July 2026 (PDF). Checked 31 October 2026.
  3. FDA, July 23 to 24, 2026 meeting of the Pharmacy Compounding Advisory Committee (meeting page; lists MOTS-c on the 23 July agenda and posted no vote results when checked). Checked 31 October 2026.
  4. STAT, FDA advisory panel rejects compounding of one peptide, backs another, 24 July 2026. Checked 31 October 2026.
  5. ClinicalTrials.gov NCT07505745, MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (MOTS-MET), Hudson Biotech, record last updated 1 April 2026. Checked 31 October 2026.
  6. ClinicalTrials.gov search for MOTS-c (also run by intervention and by mitochondrial-derived peptide), which returned NCT07505745 as the only interventional study giving MOTS-c itself. Checked 31 October 2026.
  7. ClinicalTrials.gov NCT03998514, A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease, CohBar. Checked 31 October 2026.
  8. CohBar, Positive Topline Results from the Phase 1a/1b Study of CB4211, August 2021 (company press release, copy on MarketScreener, not peer reviewed). Checked 31 October 2026.
  9. Peptulator, MOTS-c dosage calculator, reviewed 3 September 2026. Checked 31 October 2026.
  10. Peptide Bureau, research peptides legal status guide, updated October 2026. Checked 31 October 2026.
  11. HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register notice 2026-22192, 91 FR 68526, 30 October 2026. Checked 31 October 2026.
  12. HHS, the policy text with Appendices A and B (PDF). Checked 31 October 2026.

Medical disclaimer

This article is for educational and informational purposes only and is not medical advice. MOTS-c is not approved for human therapeutic use and is supplied for laboratory research only. Nothing here is a recommendation to obtain or administer any compound. The dose figures described are reported market conventions documented for reference, not clinical protocols, and they are included to describe what circulates rather than to guide use. Consult a qualified clinician before making any decision about your health.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes
PB
The Peptide Bureau editorial desk. Peptide Bureau is a small independent research team covering peptide dosing, safety and vendors. We are not clinicians; nothing here is medical advice. How the Bureau works.